Investigation of serum levels of orexin‐A, transforming growth factor β, and leptin in patients with multiple sclerosis. Issue 1 (11th December 2021)

• Record Type: Journal Article
• Authors: Moharami, Sepideh; Nourazarian, Alireza; Nikanfar, Masoud; Laghousi, Delara; Shademan, Behrouz; Joodi Khanghah, Omid; Khaki‐Khatibi, Fatemeh
• Is Part Of: Journal of clinical laboratory analysis. Volume 36:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-12-11
• Subjects: Body Mass Index -- leptin -- multiple sclerosis -- orexin‐A -- TGF‐β; Diagnosis, Laboratory -- Periodicals; Medical laboratory technology -- Periodicals; 616
• DOI: 10.1002/jcla.24170
• Languages: English
• ISSNs: 0887-8013

Abstract

Abstract: Background: Multiple sclerosis (MS) is a chronic inflammatory and autoimmune disease affecting various inflammatory and nutritional parameters. Therefore, this study aimed to investigate the relationship between the Body Mass Index (BMI) of MS patients and the serum levels of leptin, orexin‐A, and Transforming Growth Factor β (TGF‐β). Methods: This cross‐sectional study included 25 patients suffering from MS and 40 healthy individuals as the case and control groups, respectively. The serum levels of leptin, orexin‐A, and TGF‐β were assessed in the participants using the Enzyme‐Linked Immunosorbent Assay methods. Moreover, data were analyzed using the descriptive statistical indices, t ‐test, chi‐square test, and linear regression test. Results: According to our results, the participants' mean age was 38.04 ± 7.53 and 40.23 ± 5.88 in the case and control groups, respectively. Also, the groups were not significantly different in gender, age, alcohol consumption, and smoking ( p > 0.05). It was found that the mean serum levels of orexin‐A and TGF‐β were significantly lower in the MS patients compared to the control group, while the mean serum leptin levels were significantly higher (42.8 vs. 18.9 ng/ml, p < 0.001). Moreover, there was no significant relationship between the BMI of the MS patients and their serum levels of orexin‐A, TGF‐β, and leptin ( p > 0.05). Conclusions: In conclusion, we found significantly lower levels of orexin‐A and TGF‐β and a significantly higher level of leptin in the MS patients compared to the control group. In addition, there was no significant relationship between the BMI and the serum levels of orexin‐A, TGF‐β, and leptin in MS patients. Abstract : Background: Multiple Sclerosis (MS) is a chronic inflammatory and autoimmune disease related to various inflammatory and nutritional parameters. This study was conducted to determine the relationship between serum leptin, orexin‐A, and TGF‐β levels and BMI in MS patients. Methods: This cross‐sectional study included 25 patients with relapsing‐remitting multiple sclerosis (RRMS) and 40 healthy controls. Serum levels of leptin, orexin‐A and TGF‐β were measured by an enzyme‐linked immunosorbent assay (ELISA). Data was analyzed using descriptive statistics, t‐tests, chi‐square tests, and linear regression tests. 65 volunteers, including 25 MS patients and 40 healthy individuals, were enrolled in the study. Results: The mean ages of subjects in the case and control groups were 38.04 ± 7.53 and 40.23 ± 5.88, respectively. There were no statistically significant differences between the case and control groups in sex, age, alcohol consumption, and cigarette consumption ( p > 0.05). Mean serum levels of orexin‐A and TGF‐ss were lower in patients with MS than in healthy controls, but leptin was higher (42.8 vs. 18.9 ng/ml, p < 0.001). The relationship between BMI and serum levels of orexin‐A, TGF‐ss, and leptin in MS patients was not statistically significant ( p > 0.05). Conclusion: Our results showed that serum levels of orexin‐A and TGF‐P were lower. The serum level of leptin was higher in patients with MS than in healthy controls. In addition, there was no statistically significant relationship between BMI and serum levels of orexin‐A, TGF‐ss, and leptin in patients with MS.